Collplant Biotechnologies

Collplant Biotechnologies FCF Yield

The Free Cash Flow Yield of Collplant Biotechnologies (CLGN) as of Nov 1, 2026 is -91.11 %. In the previous year, Free Cash Flow Yield was -140.58 % — a change of -35.19% (higher).

FCF Yield

-91.11 %

YoY

-35.19%

Last updated:

Free Cash Flow Yield of Collplant Biotechnologies is 2025 -91.11 % . Free Cash Flow Yield of Collplant Biotechnologies was 2024 -140.58 % . It decreases by -35.19% higher compared to the previous year.

The Collplant Biotechnologies FCF Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Yield
Date
FCF Yield
Jan 1, 2018
-19.76 USD
Jan 1, 2019
-69.38 USD
Jan 1, 2020
-47.14 USD
Jan 1, 2021
10.35 USD
Jan 1, 2022
-144.40 USD
Jan 1, 2023
-35.85 USD
Jan 1, 2024
-140.58 USD
Jan 1, 2025
-91.11 USD
The Collplant Biotechnologies FCF Yield history
YEARFCF YieldYoY
-91.11 %-35.19%
-140.58 %+292.14%
-35.85 %-75.17%
-144.40 %-1,495.34%
10.35 %-121.95%
-47.14 %-32.05%
-69.38 %+251.10%
-19.76 %-59.77%
-49.12 %-1.14%
-49.69 %+26.36%
-39.32 %+19.49%
-32.91 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Collplant Biotechnologies Stock analysis

What does Collplant Biotechnologies do? CollPlant Biotechnologies Ltd. develops and markets regenerative medicine products based on plant-derived collagen type I (rhCollagen) for tissue repair and organ bioprinting. The company focuses on medical aesthetics and tissue regeneration applications, targeting healthcare providers and research institutions seeking advanced bioprinting solutions. Its core technology enables the production of collagen without animal sources, addressing market demands for ethical and sustainable biomaterials. The firm's products include bioprinting solutions for tissue and organ production, which are sold to medical research organizations and healthcare facilities. CollPlant's technology differentiates itself through plant-based collagen, appealing to clients prioritizing eco-friendly and animal-free medical solutions. This approach aligns with growing industry trends toward sustainable regenerative medicine practices. CollPlant Biotechnologies Ltd. generates revenue through the sale of its bioprinting technologies and collagen-based medical products. The company's target segments include regenerative medicine researchers, tissue engineering specialists, and medical aesthetics providers who require advanced biomaterials for their applications. These segments value the company's plant-derived collagen technology for its ethical sourcing and performance in tissue repair applications. Collplant Biotechnologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Collplant Biotechnologies stock

Free Cash Flow Yield of Collplant Biotechnologies is -91.11 % in 2025.

Free Cash Flow Yield of Collplant Biotechnologies changed from -140.58 % to -91.11 %, representing a -35.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow Yield Collplant Biotechnologies since 2006 – with annual values, charts, and detailed analysis.

FCF Yield measures the free cash flow per share relative to the stock price. It indicates how much cash a company generates for each dollar invested.

To evaluate Free Cash Flow Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Yield's Collplant Biotechnologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Collplant Biotechnologies

All Key Metrics — Collplant Biotechnologies